Key result
Inhibition of the proto-oncogene c-Myc is emerging as an attractive paradigm for the prevention and treatment of hypertrophic cardiomyopathy and heart failure.
Why the study?
Does c-Myc inhibition have therapeutic potential for the prevention and treatment of hypertrophic cardiomyopathy and heart failure?
Design
Review
Authors
Loading...
c-Myc inhibition may offer a novel target in HCM and HF; leaves open need for clinical trials.
Does c-Myc inhibition have therapeutic potential for the prevention and treatment of hypertrophic cardiomyopathy and heart failure?
Inhibition of the proto-oncogene c-Myc represents a potential future therapeutic strategy for hypertrophic cardiomyopathy and heart failure.
Wolfram et al. (2010) conducted a review in Hypertrophic cardiomyopathy. c-Myc inhibition was evaluated. Inhibition of the proto-oncogene c-Myc is emerging as an attractive paradigm for the prevention and treatment of hypertrophic cardiomyopathy and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: